
Anvisa proposes exclusive process for the regulation and experts point out impact on the sector

Norm review may limit imports via RDC 660 if there is a national equivalent; director Thiago Campos presents dissenting vote

Patient follow-up for up to two years

Amidst the expansion of the medical market, regulatory tensions, and the entry of emerging countries like Brazil, the conference establishes itself as a strategic space for scenario analysis, political articulation, and global business

Minister Guilherme Boulos meets sector to discuss working group and inclusion of associations in new medicinal cannabis legislation

Study maps the DNA of six distinct cultivars' chloroplast, revealing promising genetic tools for crop improvement and forensic tracking

Reform sets a 1% THC limit, allows the supply of biomass for medicinal purposes, and replaces mandatory licensing with a simple notification system, foreseeing an economic impact of 41 million dollars

Letter brings together experts from across the country and includes UFLA participation

Research published in an international journal points to a reduction in controlled medications and behavioral improvements during supervised treatment

World's first research will test the combination of THC and CBD in relieving symptoms of severe patients; project received funding from parliamentary amendment

The story of Tereza Emir, who has been facing intense pain for 15 years, and her daughter Alessandra, who juggles motherhood, work, and daily care to ensure her mother's comfort and relief with medicinal cannabis

Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence

Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence

Sustainable growth depends on technical education and Agro's entry into the production chain

How the pharmaceutical industry ensures quality and safety in cannabis-based products sold in Brazil

Gustavo Palhares believes that regulatory revision can relax prescriptions, expand access, and raise technical requirements in the medicinal cannabis sector

Ledyane, who resumed running after three years of treatment, reflects a growing movement among doctors and patients seeking alternatives to conventional drugs

Research indicates the potential of cannabis residue in reducing methane, while experts assess safety, applicability, and impacts on animal welfare

Research indicates the potential of cannabis residue in methane reduction, while experts assess safety, applicability, and animal welfare impacts

Anvisa has prohibited the manufacturing, sale, and promotion of CBD Brasil's cannabis products due to lack of sanitary authorization